Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.
Two lines near the bottom of a peptide certificate are easy to skip: heavy metals and residual solvents. This article explains where metals and organic solvents enter a synthetic peptide, how inductively coupled plasma mass spectrometry (ICP-MS) and headspace gas chromatography measure them, which pharmacopeial and ICH limits laboratories borrow as reference points, and how to tell a complete entry from a vague one.
Where metals and solvents come from in peptide synthesis
Metals and solvents are process residues: they reach the final powder from reagents, equipment and purification steps, not from the peptide itself. Solid-phase synthesis runs in N,N-dimethylformamide (DMF) or N-methyl-2-pyrrolidone (NMP), uses piperidine for deprotection and dichloromethane for washes, and ends with a trifluoroacetic acid (TFA) cleavage cocktail. Preparative reverse-phase purification adds acetonitrile and more TFA, precipitation often uses diethyl ether, and salt exchange may introduce acetic acid or hydrochloric acid. Lyophilization removes most of these, but a few hundred parts per million of a high-boiling solvent such as DMF can persist in the cake.
Metals arrive by different routes. Stainless-steel reactors and columns shed iron, chromium and nickel; palladium or other catalysts are used for some protecting-group removals; resin, reagent and water quality contribute trace lead, arsenic, cadmium and mercury; and glass and filter media can leach aluminum and boron. ICH Q3D(R2) notes that the four Class 1 elements, arsenic, cadmium, mercury and lead, have "limited or no use" in pharmaceutical manufacture and typically enter through commonly used materials, which is why they must be evaluated across every source. D'Hondt and colleagues' 2014 review of related impurities in peptide medicines in the Journal of Pharmaceutical and Biomedical Analysis lists residual solvents and counter-ions alongside sequence-related impurities as process residues a complete profile has to account for. The counter-ion question is covered separately in TFA salt vs acetate salt.
ICP-MS: how elemental impurities are measured
ICP-MS converts a digested sample into an argon plasma at roughly 6,000 to 10,000 K, ionizes the atoms, and sorts the ions by mass-to-charge ratio, so each element is counted at its own isotope rather than inferred from a color change. The old USP <231> heavy-metals test relied on precipitating metal sulfides and comparing a brown stain against a lead standard; it was insensitive, non-specific and blind to several elements. USP replaced it with General Chapter <232> Elemental Impurities - Limits and <233> Elemental Impurities - Procedures, which require substance-specific multi-element measurement, principally by ICP-OES or ICP-MS.
USP <233> describes two instrumental procedures, Procedure 1 by ICP-OES and Procedure 2 by ICP-MS, and sets acceptance criteria for any alternative procedure: specificity, spike recovery, precision and a demonstrated detection limit for each target element. Sample preparation is usually a closed-vessel microwave acid digestion of a weighed portion, so the result is reported per gram of powder. Galdino and César's 2026 comparison of techniques concluded that ICP-MS, with detection at nanogram-per-liter levels, is the most suitable method for regulatory compliance despite its cost.
| Element | ICH Q3D class | Oral PDE (µg per gram-of-product basis, Option 1) | Parenteral PDE basis, Option 1 | Typical isotope monitored |
|---|---|---|---|---|
| Cadmium (Cd) | 1 | 5 µg PDE; 0.5 µg/g | 2 µg PDE; 0.2 µg/g | 111Cd, 114Cd |
| Lead (Pb) | 1 | 5 µg PDE; 0.5 µg/g | 5 µg PDE; 0.5 µg/g | 208Pb |
| Arsenic (As) | 1 | 15 µg PDE; 1.5 µg/g | 15 µg PDE; 1.5 µg/g | 75As (ArCl interference corrected) |
| Mercury (Hg) | 1 | 30 µg PDE; 3 µg/g | 3 µg PDE; 0.3 µg/g | 202Hg |
| Cobalt (Co) | 2A | 50 µg PDE; 5 µg/g | 5 µg PDE; 0.5 µg/g | 59Co |
| Vanadium (V) | 2A | 100 µg PDE; 10 µg/g | 10 µg PDE; 1 µg/g | 51V |
| Nickel (Ni) | 2A | 200 µg PDE; 20 µg/g | 20 µg PDE; 2 µg/g | 60Ni |
| Palladium (Pd) | 2B | 100 µg PDE; 10 µg/g | 10 µg PDE; 1 µg/g | 105Pd |
PDE values are taken from Table A.2.1 of ICH Q3D(R2); the Option 1 concentrations divide each PDE by a 10 g product mass, as the guideline describes. These values were written for licensed pharmaceutical manufacturing and a defined route of use. A research-use certificate that reports "Pb < 0.5 µg/g" is adopting the Q3D figure as a reference point for comparison; doing so is not a claim that the vial is a drug product or that any route applies to it.
Residual solvents: headspace GC and the ICH Q3C classes
Residual solvents are measured by static headspace gas chromatography: a weighed sample is dissolved in a high-boiling diluent, heated in a sealed vial until the volatile solvents partition into the gas phase, and a portion of that headspace is swept onto a capillary column and detected, usually by flame ionization (FID) or mass spectrometry. USP General Chapter <467> Residual Solvents, which USP states is aligned with ICH Q3C, defines Procedures A and B (two columns of different polarity for screening and confirmation) and Procedure C for quantitation. Belsky and colleagues described in 2010 how the chapter's water-insoluble procedures were optimized around DMSO or DMF as the diluent, a 3:1 split and matrix-matched system-suitability solutions. Dang and colleagues reported in 2026 a platform headspace-GC procedure, built under ICH Q14 principles, that quantifies 18 solvents in one run. Sayyad and colleagues reported 2024 headspace GC-MS quantitation limits for the Class 1 solvents between 0.2 and 15 ppm.
| ICH Q3C class | Meaning | Examples relevant to peptide work | Option 1 concentration limit |
|---|---|---|---|
| Class 1 | Solvents to be avoided (known or suspected carcinogens, environmental hazards) | Benzene 2 ppm; carbon tetrachloride 4 ppm; 1,2-dichloroethane 5 ppm; 1,1-dichloroethene 8 ppm; 1,1,1-trichloroethane 1500 ppm | As listed per solvent |
| Class 2 | Solvents to be limited | Acetonitrile 410 ppm; dichloromethane 600 ppm; DMF 880 ppm; NMP 530 ppm; methanol 3000 ppm; chloroform 60 ppm; hexane 290 ppm; toluene 890 ppm | PDE (mg) × 1000 / 10 g |
| Class 3 | Low toxic potential; limited by good practice | Acetic acid, acetone, DMSO, ethanol, ethyl acetate, diethyl ether, 2-propanol, tert-butyl methyl ether | 5000 ppm (0.5%) without further justification |
The classification and the numbers come from Tables 1 to 3 of ICH Q3C(R8). Note what is absent: piperidine, TFA and the scavengers used in cleavage cocktails are not Q3C-listed solvents, so a certificate that reports only "Residual solvents: conforms to USP <467>" has said nothing about them. TFA (PubChem CID 6422, C2HF3O2, 114.02 g/mol) is non-volatile as a salt and is measured by other means: ion chromatography and capillary electrophoresis, as Mrozik and colleagues showed in 2012, 19F NMR, as in the 2026 Journal of Organic Chemistry method, or FT-IR and HPLC with evaporative light-scattering detection, as Erckes and colleagues validated in 2025. Those authors also found that lyophilizing from 10 mM HCl exchanged TFA for chloride without affecting purity. The amounts matter for mass accounting: Melanson and colleagues found TFA at nearly 25% of the mass of an angiotensin II reference material in 2018, and Chen and colleagues reported 15.48% trifluoroacetate in a purified sublancin sample in 2026.
How to read the two lines on a certificate
A complete metals entry lists each element tested, the result per element with its unit, the method and the reporting limit; a complete solvents entry lists each solvent screened, the result, and the method. The weakest common entry is a single number: "Heavy metals: < 10 ppm". That phrasing is a relic of the sulfide-stain test and does not say which elements were measured or whether arsenic and mercury, which the old test handled poorly, were included at all. The second weakest is a method without results: "ICP-MS: Pass" tells the reader nothing about the limit applied.
| Entry as printed | What it tells you | What to ask for |
|---|---|---|
| Heavy metals: < 10 ppm | Legacy limit-test language; elements unspecified | Element-by-element ICP-MS results and the reporting limit for each |
| Pb 0.08 µg/g; As < 0.05 µg/g; Cd < 0.02 µg/g; Hg < 0.05 µg/g (ICP-MS, USP <233>) | Specific, quantitative, method named | Which Class 2A and catalyst elements were also screened |
| Residual solvents: conforms | Unknown solvent list and limits | The solvent list, results in ppm, and the diluent used |
| DMF 120 ppm; acetonitrile < 50 ppm; DCM not detected (HS-GC-FID, USP <467> Procedure C) | Quantitative, matched to the synthesis solvents | Whether TFA or acetate content is reported elsewhere on the certificate |
One note on units: "ppm" here is a mass fraction equal to micrograms per gram (µg/g) of powder, independent of the vial's labeled mass; a 10 mg vial and a 50 mg vial from the same lot carry the same value. Read it together with the net-content line explained in net peptide content vs purity.
Why a research-use certificate reports them at all
Research-use certificates adopt the pharmacopeial chapters because they are the only widely recognized, method-validated framework for process residues, not because the vial is being represented as a pharmaceutical. ICH Q3D and Q3C exist to control exposure through finished medicines, and their numbers assume a defined product mass and a defined route of exposure, neither of which applies to an in vitro reagent. What transfers cleanly is the analytical method and the reporting discipline: a validated ICP-MS procedure under USP <233> and a headspace GC procedure under USP <467> produce numbers that any second laboratory can reproduce, and a certificate that prints those numbers can be checked, as discussed in why a second laboratory matters.
For the laboratory user the practical value is direct. Residual DMF or acetonitrile at the percent level changes the true mass of peptide in a weighed sample and can interfere with UV absorbance readings; trace transition metals catalyze oxidation of methionine, cysteine and tryptophan residues in solution and can confound metal-sensitive assays. Knowing the numbers lets a researcher decide whether a lot is suitable for a sensitive cell-culture or binding experiment before the vial is opened. US Prime Peptides reports heavy metals by ICP-MS on every lot alongside identity, purity, net content, endotoxin and sterility, on a certificate from an independent US laboratory posted on the product page before purchase.
Frequently Asked Questions
What does ICP-MS heavy metals testing on a peptide COA actually measure?
ICP-MS digests a weighed sample, ionizes it in an argon plasma, and counts each element at its own isotope, reporting lead, arsenic, cadmium, mercury and other elements individually in micrograms per gram of powder. It replaced the old USP <231> sulfide-stain test, which gave one non-specific "heavy metals" number and missed several elements.
What are acceptable heavy metal limits for a research peptide?
There is no research-specific standard, so laboratories borrow ICH Q3D(R2) and USP <232> values as reference points: for example 0.5 µg/g for lead and cadmium and 1.5 µg/g for arsenic under the oral Option 1 calculation, with lower parenteral figures for cadmium and mercury. Using those figures on a research certificate is a comparison convention, not a claim of drug status.
How are residual solvents in peptides tested?
By static headspace gas chromatography under USP <467>: the sample is dissolved in DMSO or DMF, heated in a sealed vial, and the vapor is separated on a capillary column with flame-ionization or mass-spectrometric detection. ICH Q3C(R8) assigns limits by class, such as 410 ppm for acetonitrile, 880 ppm for DMF and 5000 ppm for Class 3 solvents.
Is TFA a residual solvent?
Not in the regulatory sense. Trifluoroacetic acid is not on the ICH Q3C solvent lists and stays in the powder as a non-volatile counter-ion, so headspace GC does not see it. It is measured by ion chromatography, 19F NMR or FT-IR and can reach 15 to 25% of the powder mass, which is why it belongs on the content line rather than the solvents line.
Citations
- ICH. Guideline for Elemental Impurities Q3D(R2). Final version, adopted 26 April 2022. database.ich.org (PDF)
- ICH. Impurities: Guideline for Residual Solvents Q3C(R8). Step 4 version, 22 April 2021. database.ich.org (PDF)
- United States Pharmacopeia. General Chapter <232> Elemental Impurities - Limits. USP-NF. doi.usp.org/USPNF/USPNF_M5192_03_01.html
- United States Pharmacopeia. General Chapter <233> Elemental Impurities - Procedures. USP-NF. doi.usp.org/USPNF/USPNF_M5193_03_01.html
- United States Pharmacopeia. FAQs: <467> Residual Solvents. usp.org/frequently-asked-questions/residual-solvents
- FDA. Q3D(R2) Guideline for Elemental Impurities: Guidance for Industry. September 2022. fda.gov
- PubChem. Trifluoroacetic acid, CID 6422. National Library of Medicine. pubchem.ncbi.nlm.nih.gov/compound/Trifluoroacetic-acid
- Galdino JNS, César IDC. Comparison of Analytical Methods for the Determination of Elemental Impurities in Pharmaceutical Products. Crit Rev Anal Chem. 2026:1-13. PMID 41848101
- Belsky JL, Ashley AJ, Bhatt PA, et al. Optimization of the water-insoluble procedures for USP General Chapter Residual Solvents <467>. AAPS PharmSciTech. 2010;11(2):994-1004. PMID 20521178
- Dang N, Ander A, Bohlin M, et al. Platform analytical procedure for the analysis of residual solvents in active pharmaceutical ingredients by headspace-gas chromatography - A use case of implementation. J Pharm Biomed Anal. 2026;269:117243. PMID 41259991
- Sayyad K, Kowtharapu LP, Mondal T, et al. Headspace Gas Chromatography-Mass Spectrometry Method for Determination of Class-I Residual Solvents in Several Drug Substances: Method Evaluation by Quality by Design Statistical Tool. J AOAC Int. 2024;107:921-933. PMID 39002114
- D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. PMID 25044089
- Mrozik W, Markowska A, Guzik L, Kraska B, Kamysz W. Determination of counter-ions in synthetic peptides by ion chromatography, capillary isotachophoresis and capillary electrophoresis. J Pept Sci. 2012;18(3):192-198. PMID 22252914
- Maarouf Mesli N, Yongo Luwawa CD, Boccino I, et al. Method for Quantifying Trifluoroacetic Acid in Peptides by 1H-19F NMR Spectral Correlation. J Org Chem. 2026;91:11923-11930. PMID 42695718
- Erckes V, Streuli A, Chamera Rendueles L, Krämer SD, Steuer C. Towards a Consensus for the Analysis and Exchange of TFA as a Counterion in Synthetic Peptides and Its Influence on Membrane Permeation. Pharmaceuticals (Basel). 2025;18(8). PMID 40872554
- Melanson JE, Thibeault MP, Stocks BB, Leek DM, McRae G, Meija J. Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem. 2018;410:6719-6731. PMID 30143839
- Chen W, Yan J, Yang M, et al. SI-traceable purity assignment for peptide sublancin using mass balance approach and isotope dilution mass spectrometry based on amino acid analysis. J Chromatogr B. 2026;1277:125038. PMID 41916078
This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.
Related research
- LC-MS Identity Confirmation: What the Mass Spectrum Proves About a Peptide
- HPLC Purity: What 'Area Percent' Does and Does Not Tell You
- What a Peptide Certificate of Analysis Does Not Test For
- TFA Salt vs Acetate Salt: Why the Counter-Ion on a Peptide Matters
- How to Vet a Research Peptide Vendor: A 12-Point Checklist
Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.
